Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL

2018-02-15 19:00:45

Nature Communications

A. Schrader, G. Crispatzu, S. Oberbeck, P. Mayer, S. Pützer, J. von Jan, E. Vasyutina, K. Warner, N. Weit, N. Pflug, T. Braun, E. I. Andersson, B. Yadav, A. Riabinska, B. Maurer, M. S. Ventura Ferreira, F. Beier, J. Altmüller, M. Lanasa, C. D. Herling, T. Haferlach, S. Stilgenbauer, G. Hopfinger, M. Peifer, T. H. Brümmendorf, P. Nürnberg, K. S. J. Elenitoba-Johnson, S. Zha, M. Hallek, R. Moriggl, H. C. Reinhardt, M.-H. Stern, S. Mustjoki, S. Newrzela, P. Frommolt & M. Herling



T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences in 111 well-characterized patients. Besides prominent signatures of T-cell activation and prevalent clonal variants, we also identify novel hot-spots for CN variability, fusion molecules, alternative transcripts, and progression-associated dynamics. The overall lesional spectrum of T-PLL is mainly annotated to axes of DNA damage responses, T-cell receptor/cytokine signaling, and histone modulation. We formulate a multi-dimensional model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression with damaging ATM aberrations as initiating core lesions. The effects imposed by TCL1 cooperate with compromised ATM toward a leukemogenic phenotype of impaired DNA damage processing. Dysfunctional ATM appears inefficient in alleviating elevated redox burdens and telomere attrition and in evoking a p53-dependent apoptotic response to genotoxic insults. As non-genotoxic strategies, synergistic combinations of p53 reactivators and deacetylase inhibitors reinstate such cell death execution.

Empire Genomic's RP11 FISH Probes
were used in this publication.

To Access Article, Click Here